A clinical trial of a drug used for treating lung cancer has revealed “a remarkable advancement”.
As per the trial, the new anti-cancer drug has unveiled that 60% of patients are still alive. Moreover, the cancer did not spread to any other part of the body, according to Interesting Engineering.
The protein anaplastic lymphoma kinase (ALK) plays a prominent role in regulating cell growth. It is produced as a result of the ALK gene. This gene can be rearranged in certain cancers including non-small cell lung cancer (NSCLC).
Among these, ALK-positive tumors occur in approximately 3% to 5% of cases among these cancers.
The trial’s results revealed that Lorlatinib is a third-generation ALK inhibitor. Used as the standard first-line treatment for patients with ALK-positive NSCLC, it is the latest in a class of drugs.
Led by the Peter MacCallum Cancer Center in Melbourne, Australia, a recent international clinical trial evaluated the drug’s impact on long-term disease progression in patients with advanced ALK-positive NSCLC.
Peter Mac’s Professor Ben Solomon, the study’s lead and corresponding author, said in an interview with The Guardian: “To our knowledge, these results are unprecedented.”
Spokesperson says "both research-related and natural origin scenarios of the COVID-19 pandemic remain plausible"
KP official says public health reference lab confirmed mpox detection, shifted patient to Police Services Hospital
As many as 11 polio cases reported from DI Khan in 2024
Seeing healthcare provider has been deemed important if your cold symptoms persist, worsen
Department orders health officers to educate community regarding use of seasonal influenza vaccination
$52bn in budget could be saved for over 10 years if efforts made to help even 10% of teens, researchers find